CN100388945C - Fatty liver treating notoginseng prepn and its prepn process - Google Patents
Fatty liver treating notoginseng prepn and its prepn process Download PDFInfo
- Publication number
- CN100388945C CN100388945C CNB2005100110801A CN200510011080A CN100388945C CN 100388945 C CN100388945 C CN 100388945C CN B2005100110801 A CNB2005100110801 A CN B2005100110801A CN 200510011080 A CN200510011080 A CN 200510011080A CN 100388945 C CN100388945 C CN 100388945C
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- notoginseng
- preparation
- weight portions
- clear paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 78
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 76
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 76
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 76
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 59
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 39
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 238000002386 leaching Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract 2
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 230000003908 liver function Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004518 granules dosage form Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000030212 nutrition disease Diseases 0.000 description 2
- 208000019180 nutritional disease Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 238000008087 TBil Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a notoginseng medicine for treating fatty liver and a preparation method thereof, and the medicine is prepared from 20 to 30 weight portions of notoginseng, 20 to 30 weight portions of zedoray rhizome, 20 to 30 weight portions of dodder seed, 20 to 30 weight portions of chrysanthemum, 20 to 30 weight portions of largehead atractylodes rhizome, 10 to 30 weight portions of water plantain, 10 to 30 weight portions of white peony alba, 20 to 30 weight portions of lotus leaf, 10 to 30 weight portions of green tangerine peel, 20 to 30 weight portions of red peony root and 20 to 40 weight portions of Yunnan hawthorn fruit. The notoginseng medicine for treating fatty liver and the preparation method thereof utilize partial Chinese medicinal plants which are discovered and verified by modern clinical observation and experimental research, and therefore, the damage to liver cells and metabolic block can be lightened, the deformation of fat is blocked, and the medicine has the result of fatty liver resistance action, wherein the Chinese medicinal plants have the advantages of scientific and reasonable prescription, advanced preparation technology, simple and feasible operation, and low cost. The notoginseng medicine for treating fatty liver has the advantages of good effect on treating symptoms of fatty liver, hyperlipemia, etc., no recurrence after the medicine is stopped, etc.
Description
Technical field
The present invention relates to Chinese patent medicine preparation, specifically a kind of fatty liver treating notoginseng preparation that is used for the treatment of diseases such as fatty liver, hyperlipemia and preparation method thereof.
Background technology
Liver is one of most important vitals of human body, is the digestive gland of human body maximum, has secretion of bile, stores important functions such as hepatic glycogen and detoxifcation.Processes such as the digestion of fat, absorption be unable to do without liver, and various medicines also need pass through liver metabolism, if liver function generation obstacle then will influence whole machine body health.According to expert introduction, the part Patients with Fatty Liver can develop into hepatic fibrosis, even liver cirrhosis, causes quality of life to descend then and the life expectancy shortening.Therefore; healthy the reaching of the liver protecting effectively treated hepatic disease; always be the important topic that medical workers are devoted to research and solve; also for this reason; medical workers have provided the medicine of multiple treatment hepatic disease for society, for the misery that alleviates the hepatopathy patient has been made significant contribution.Yet, up to now, with regard to the treatment fatty liver, but there is not a kind of specific drug, cause sickness rate constantly to increase, one group of data show that medium are usually quoted, the incidence rate of fatty liver increased by 50 times before 5 years in recent years; In the health examination of some hospitals, the fatty liver recall rate is the highest, reaches 50%.Become the second largest hepatic disease that is only second to viral hepatitis.
Summary of the invention
The purpose of this invention is to provide and a kind ofly can effectively treat fatty liver treating notoginseng preparation that does not rebound after disease, the drug withdrawals such as fatty liver, hyperlipemia and preparation method thereof.
Technical scheme of the present invention is: fatty liver treating notoginseng preparation is made by 11 kinds of Chinese crude drugs such as Radix Notoginseng, Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Rhizoma Alismatis, the Radix Paeoniae Alba, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, Yunshan Mountain short, bristly hair or beards.
This proportioning of optimum weight of 11 kinds of Chinese crude drugs is:
Radix Notoginseng 30 Rhizoma Curcumae 26 Semen Cuscutae 28
Flos Chrysanthemi 30 Rhizoma Atractylodis Macrocephalaes 27 Rhizoma Alismatis 16
The Radix Paeoniae Alba 15 Folium Nelumbinis 20 Pericarpium Citri Reticulatae Virides 25
Radix Paeoniae Rubra 30 Yunshan Mountain short, bristly hair or beards 20
The present invention also can prepare in following scope:
Radix Notoginseng 20-30 Rhizoma Curcumae 20-30 Semen Cuscutae 20-30
Flos Chrysanthemi 20-30 Rhizoma Atractylodis Macrocephalae 20-30 Rhizoma Alismatis 10-30
Radix Paeoniae Alba 10-30 Folium Nelumbinis 20-30 Pericarpium Citri Reticulatae Viride 10-30
Radix Paeoniae Rubra 20-30 Yunshan Mountain short, bristly hair or beard 20-40
Fatty liver treating notoginseng preparation can be made into tablet, pill, capsule and granule system etc.
Preparation method is:
1., make the A material, Radix Notoginseng, Rhizoma Alismatis, three kinds of Chinese crude drugs of the Radix Paeoniae Alba are mixed, carry out micronizing (about 400 orders) A material powder;
2., make B material clear paste: will Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, eight kinds of Chinese crude drugs of Yunshan Mountain short, bristly hair or beard mix the back and get with flooding, concentrating leaching liquid to relative density is 1.10 (80～85 ℃), B material clear paste;
3., preparation fatty liver treating notoginseng tablet: add B material clear paste add 5% starch, 3% dextrin mix homogeneously in A material powder after and stir, make granule, drying adds 0.5% magnesium stearate tabletting of total amount again.
Preparation fatty liver treating notoginseng pill: expect the general ball of powder, drying, polishing with A after in B material clear paste, adding 20% refined honey mixing.
Preparation fatty liver treating notoginseng capsule: the A material is mixed stirring with the B material, and drying was pulverized 60～80 mesh sieves, was distributed into capsule.
In addition, fatty liver treating notoginseng preparation can also be prepared into the granule dosage form, and preparation method is: 11 kinds of Chinese crude drugs are mixed, get with flooding after pulverizing coarse powder, concentrating leaching liquid to relative density is the clear paste of 1.10 (80～85 ℃), adds 20% Icing Sugar and 5% dextrin, makes granule behind the mix homogeneously.
The traditional Chinese medical science thinks that fatty liver is insufficiency of the spleen phlegm resistance, irritability imbalance so, phlegm-damp disappears certainly if spleen can be good for transport then, irritability also can freely be transferred.The etiology and pathogenesis of bound fat liver should be reused spleen invigorating and be helped the stagnant method of the fortune turbid removing food stagnancy of removing dampness; Prescription medium cloud hawthorn digesting of the present invention is good for the stomach the circulation of qi promoting dissipating blood stasis.Rhizoma Alismatis has stronger promoting diuresis to eliminate damp pathogen effect, and modern pharmacological research proof Fructus Crataegi, Rhizoma Alismatis all have significant effect for reducing blood fat; Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, moist diuretic are used for insufficiency of the spleen lack of appetite, the loose stool of having loose bowels, and the modern pharmacological research Rhizoma Atractylodis Macrocephalae has the blood vessel dilating effect, makes blood pressure drops, and the anticoagulant effect is arranged; Radix Notoginseng, Rhizoma Curcumae have significant blood circulation promoting and blood stasis dispelling, and reducing swelling and alleviating pain effect, but blood viscosity lowering help to improve hyperlipemia.Pericarpium Citri Reticulatae Viride has soothing the liver dispelling the stagnated QI, stagnant, the QI regulating by alleviation of mental depression effect of removing food stagnancyization; All the other flavour of a drug: Radix Paeoniae Alba suppressing the hyperactive liver pain relieving; The heat clearing away of chrysanthemum powder forimproving wind, suppressing the hyperactive liver makes eye bright; The Radix Paeoniae Rubra clearing away heat and cooling blood, eliminating stasis to stop pain.The Semen Cuscutae nourishing the liver and kidney.All medicines share, and can play the effect that good blood fat reducing improves liver function.
Fatty liver treating notoginseng preparation of the present invention and preparation method thereof, the part Chinese crude drug that has utilized modern clinical observation and experimentation to find and confirm can make hepatocyte injury and dysbolismus alleviate, stop the fat distortion, achievement with lipotropy, its Chinese crude drug prescription science, reasonable, processing technology advanced person, operation is simple, with low cost, fatty liver treating notoginseng preparation has can effectively treat advantage such as do not rebound after diseases such as fatty liver, hyperlipemia, the drug withdrawal.
The clinical observation on the therapeutic effect result that fatty liver treating notoginseng ball (preparation of the present invention) is used for the treatment of fatty liver 226 examples is as follows:
1, data and method
1.1 diagnostic criteria
The object of observation (case) is nutritional disorder's property fatty liver, fatty liver after the hepatitis, alcoholic fatty liver.
Above-mentioned case has:
(1) ultrasound diagnosis is diagnosed as fatty liver (light, in, severe).
(2) lipids detection: TRLG, CHOL, LDL have unusual person more than two.
(3) liver function is normal or unusual.
1.2 general clinical data
Male 142 examples among the 226 routine patients, women 84 examples, minimum 16 years old of age, maximum 70 years old, average 50.7 years old.The course of disease is the shortest 6 months, and is the longest 10 years, average 4.2 years.Wherein be diagnosed as nutritional disorder's fatty liver 81 examples, fatty liver 83 examples after the hepatitis, alcoholic fatty liver 62 examples.Serum levels of triglyceride (TRIG) 212 examples that raise wherein, serum cholesterol (CHOL) increases 176 examples, and serum low-density LP (LDL) increases 70 examples.Ultrasound diagnosis is diagnosed as severe fatty liver 38 examples, moderate fatty liver 105 examples, slight fatty liver 83 examples, unusual 136 examples of liver function ALT.
1.3 Therapeutic Method
Oral fatty liver treating notoginseng ball, one time 6 gram, one day three times, 3 months is a course of treatment.
1.4 observation index
Clinical symptoms: side of body rib distension, abdominal distention, weak etc.;
Blood fat: TRIG, CHOL, LDL;
Liver function: ALT, ALB, A.G, TBil;
B ultrasonic: liver; Spleen.
1.5 curative effect judging standard
Clinical basic healing: blood fat, liver function recovery are normal, and B ultrasonic shows that fatty liver disappears; Clinical symptom disappearance is followed the trail of and is not seen recurrence half a year.
Produce effects: blood fat, liver function recovery normally or obviously improve.B ultrasonic shows that fatty liver improves, clinical symptom disappearance or obviously improvement.
Invalid: blood fat or liver function do not have change, and B ultrasonic shows the fatty liver no change, and clinical symptoms is improved not obvious.
2, therapeutic outcome
2.1 the clinical symptoms improvement situation of treatment sees Table 1
Table 1. fatty liver treating notoginseng pill for curing fatty liver main clinic symptoms is improved situation
Behind the fatty liver treating notoginseng pill for curing, obese patient's body weight all has decline in various degree.
2.2 treatment back blood fat liver function recovery situation sees Table 2
Table 2. treatment back blood fat and liver function recovery situation
Table 2 shows that the fatty liver treating notoginseng ball has tangible effect for reducing blood fat, and total effective rate reaches 93.67%, and wherein the glyceride effective percentage is 96.23%.The serum cholesterol effective percentage is 92.62%, and the ALT normalization rate is 79.41%, illustrates that it has significantly function for protecting liver and reducing enzyme activity.
2.3 the ultrasound diagnosis situation of change sees Table 3 before and after the treatment
Ultrasound diagnosis situation of change before and after table 3. treatment
Table 3 shows, fatty liver treating notoginseng pill for curing fatty liver ultrasound diagnosis result, and its disappearance rate is 30.09%, the improvement rate is 63.27%.
2.4 comprehensive therapeutic effect analysis in table 4
Table 4. fatty liver treating notoginseng pill for curing edema fatty liver comprehensive therapeutic effect is analyzed
Table 4 shows, fatty liver treating notoginseng ball swollen fatty liver 226 examples of harnessing the river, and clinical total effective rate is 89.83%, and wherein clinical basic cure rate is 31.42%, and obvious effective rate is 58.41%.
3, discuss
The normal hepatocytes fat content is the heavy 3-5% of liver, mainly is triglyceride and extra-low density fatty acid, if liver fat surpass liver heavy 5% be fatty liver.Along with the variation with life style of improving constantly of people's living standard, the morbidity of fatty liver has the trend that rises year by year, and therefore lipotropic research has realistic meaning.
Though the name of disease of Chinese medicine and the fat-free liver of national medicine, but can belong to " feeling of fullness " according to its pathology pathogenesis and disease such as " gather ", the fatty liver treating notoginseng ball is made up of medicines such as Radix Notoginseng, Rhizoma Curcumae, effect with blood activating and fat reducing, strengthening spleen and softening liver, clinical treatment 226 routine Patients with Fatty Liver results show that its treatment fatty liver total effective rate is 89.83%, wherein clinical basic cure rate is 31.42%, and obvious effective rate is 58.41%.Therapeutic outcome shows that fatty liver eliminating pill has tangible the liver protecting and ALT lowering simultaneously, effect for reducing fat, serum levels of triglyceride (TRLG) normalization rate is 38.21%, improvement rate is 58.02%, and serum cholesterol (CHOL) normalization rate is 32.39%, and improvement rate is 60.23%, serum low-density LP (LDL) normalization rate is 28.59%, the improvement degree is 60%, and weight loss is in various degree all arranged after obese patient's treatment, and the ALT normalization rate is 79.41%.Why not very clinical observation finds no reaction.
The fatty liver treating notoginseng ball is to use safety, and the oral formulations of raw material abundant information, can be used as the medicine of selecting for use of treatment fatty liver.In addition fatty liver is treated except that medicine, also should instruct the patient to regulate diet, and suitably participate in physical training, the consolidation of favourable its rehabilitation and curative effect.
The specific embodiment
Below in conjunction with concrete enforcement technical solution of the present invention is described further:
Embodiment 1
The composition by weight of making the used 11 kinds of Chinese crude drugs of fatty liver treating notoginseng preparation is (a unit: gram)
Radix Notoginseng 30 Rhizoma Curcumae 26 Semen Cuscutae 28
Flos Chrysanthemi 30 Rhizoma Atractylodis Macrocephalaes 27 Rhizoma Alismatis 16
The Radix Paeoniae Alba 15 Folium Nelumbinis 20 Pericarpium Citri Reticulatae Virides 25
Radix Paeoniae Rubra 30 Yunshan Mountain short, bristly hair or beards 20
Preparation method is:
1., make A material powder: Radix Notoginseng, Rhizoma Alismatis, three kinds of Chinese crude drugs of the Radix Paeoniae Alba are mixed, carry out micronizing (about 400 orders) and get A material powder;
2., make B material clear paste: will Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, eight kinds of Chinese crude drugs of Yunshan Mountain short, bristly hair or beard mix the back and get with flooding, concentrating leaching liquid to relative density is 1.10 (80～85 ℃), B material clear paste;
3., preparation fatty liver treating notoginseng tablet: add 5% starch, 3% dextrin mix homogeneously in A material powder after, add B material clear paste and stir, make granule, drying adds 0.5% magnesium stearate tabletting of total amount again.
Preparation fatty liver treating notoginseng pill: after in B material clear paste, adding 20% refined honey mixing, with the general ball of A material powder, drying, polishing gets pill.
Preparation fatty liver treating notoginseng capsule: the A material is mixed stirring with the B material, and drying was pulverized 60～80 mesh sieves, was distributed into capsule.
The method that is prepared into the granule dosage form is: above-mentioned 11 kinds of Chinese crude drugs are mixed, get with flooding behind the pulverizing coarse powder, concentrating leaching liquid to relative density is the clear paste of 1.10 (80～85 ℃), adds 20% Icing Sugar and 5% dextrin, makes granule behind the mix homogeneously.
Embodiment 2
The composition by weight of making the used 11 kinds of Chinese crude drugs of fatty liver treating notoginseng preparation is (unit: restrain):
Radix Notoginseng 28 Rhizoma Curcumae 20 Semen Cuscutae 20
Flos Chrysanthemi 22 Rhizoma Atractylodis Macrocephalaes 25 Rhizoma Alismatis 26
The Radix Paeoniae Alba 30 Folium Nelumbinis 30 Pericarpium Citri Reticulatae Virides 20
Radix Paeoniae Rubra 28 Yunshan Mountain short, bristly hair or beards 30
Preparation method is identical with embodiment 1.
Embodiment 3
The composition by weight of making the used 11 kinds of Chinese crude drugs of fatty liver treating notoginseng preparation is (unit: restrain):
Radix Notoginseng 20 Rhizoma Curcumae 25 Semen Cuscutae 25
Flos Chrysanthemi 20 Rhizoma Atractylodis Macrocephalaes 22 Rhizoma Alismatis 10
The Radix Paeoniae Alba 18 Folium Nelumbinis 25 Pericarpium Citri Reticulatae Virides 16
Radix Paeoniae Rubra 25 Yunshan Mountain short, bristly hair or beards 35
Preparation method is identical with embodiment 1.
Embodiment 4
The composition by weight of making the used 11 kinds of Chinese crude drugs of fatty liver treating notoginseng preparation is (unit: restrain):
Radix Notoginseng 26 Rhizoma Curcumae 30 Semen Cuscutae 30
Flos Chrysanthemi 26 Rhizoma Atractylodis Macrocephalaes 26 Rhizoma Alismatis 10
The Radix Paeoniae Alba 10 Folium Nelumbinis 20 Pericarpium Citri Reticulatae Virides 10
Radix Paeoniae Rubra 28 Yunshan Mountain short, bristly hair or beards 40
Preparation method is identical with embodiment 1.
Claims (5)
1. fatty liver treating notoginseng preparation is characterized in that it is the medicament of being made by following weight portion raw material:
Radix Notoginseng 30 Rhizoma Curcumae 26 Semen Cuscutae 28
Flos Chrysanthemi 30 Rhizoma Atractylodis Macrocephalaes 27 Rhizoma Alismatis 16
The Radix Paeoniae Alba 15 Folium Nelumbinis 20 Pericarpium Citri Reticulatae Virides 25
Radix Paeoniae Rubra 30 Yunshan Mountain short, bristly hair or beards 20.
2. fatty liver treating notoginseng preparation according to claim 1 is characterized in that: be prepared into the fatty liver treating notoginseng tablet according to the following steps:
1., make A material powder: Radix Notoginseng, Rhizoma Alismatis, three kinds of Chinese crude drugs of the Radix Paeoniae Alba are mixed, carry out micronizing to 400 order, get A material powder;
2., make B material clear paste: will Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, eight kinds of Chinese crude drugs of Yunshan Mountain short, bristly hair or beard mix the back and get with flooding, concentrating leaching liquid to relative density is 1.10 80～85 ℃ the time, B material clear paste;
3., preparation fatty liver treating notoginseng tablet: add B material clear paste add 5% starch, 3% dextrin mix homogeneously in A material powder after and stir, make granule, drying adds 0.5% magnesium stearate tabletting of total amount again.
3. the preparation method of the described fatty liver treating notoginseng preparation of claim 1 is characterized in that: be prepared into the fatty liver treating notoginseng pill according to the following steps:
1., make A material powder: Radix Notoginseng, Rhizoma Alismatis, three kinds of Chinese crude drugs of the Radix Paeoniae Alba are mixed, carry out micronizing to 400 order, get A material powder;
2., make B material clear paste: will Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, eight kinds of Chinese crude drugs of Yunshan Mountain short, bristly hair or beard mix the back and get with flooding, concentrating leaching liquid to relative density is 1.10 80～85 ℃ the time, B material clear paste;
3., in B material clear paste, add behind the 20% refined honey mixing with the general ball of A material powder, drying, polishing, the fatty liver treating notoginseng pill.
4. the preparation method of the described fatty liver treating notoginseng preparation of claim 1 is characterized in that: be prepared into the fatty liver treating notoginseng capsule according to the following steps:
1., make A material powder: Radix Notoginseng, Rhizoma Alismatis, three kinds of Chinese crude drugs of the Radix Paeoniae Alba are mixed, carry out micronizing to 400 order, get A material powder;
2., make B material clear paste: will Rhizoma Curcumae, Semen Cuscutae, Flos Chrysanthemi, the Rhizoma Atractylodis Macrocephalae, Folium Nelumbinis, Pericarpium Citri Reticulatae Viride, Radix Paeoniae Rubra, eight kinds of Chinese crude drugs of Yunshan Mountain short, bristly hair or beard mix the back and get with flooding, concentrating leaching liquid to relative density is 1.10 80～85 ℃ the time, B material clear paste;
3., A material is mixed stirring with the B material, drying was pulverized 60～80 mesh sieves, was distributed into capsule, must the fatty liver treating notoginseng capsule.
5. the preparation method of the described fatty liver treating notoginseng preparation of claim 1, it is characterized in that: 11 kinds of Chinese crude drugs being mixed, get with flooding after being ground into coarse powder, is 1.10 clear paste when concentrating leaching liquid to 80～85 ℃ of relative densities, add 20% Icing Sugar and 5% dextrin, make granule behind the mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100110801A CN100388945C (en) | 2005-10-21 | 2005-10-21 | Fatty liver treating notoginseng prepn and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100110801A CN100388945C (en) | 2005-10-21 | 2005-10-21 | Fatty liver treating notoginseng prepn and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772257A CN1772257A (en) | 2006-05-17 |
| CN100388945C true CN100388945C (en) | 2008-05-21 |
Family
ID=36759509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100110801A Active CN100388945C (en) | 2005-10-21 | 2005-10-21 | Fatty liver treating notoginseng prepn and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100388945C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711852B (en) * | 2009-11-04 | 2011-04-13 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating injury symptoms of liver cells and preparation method |
| CN107050380A (en) * | 2017-02-20 | 2017-08-18 | 成都富豪斯生物科技有限公司 | A kind of Chinese medicine composition for treating fatty liver and hyperlipidemia and preparation method thereof |
| CN109589391A (en) * | 2018-12-26 | 2019-04-09 | 云南省中医医院 | A kind of strong liver disappears pharmaceutical composition and preparation method thereof, preparation and the application of rouge |
| CN115501280B (en) * | 2022-08-09 | 2023-11-10 | 广东药科大学 | Traditional Chinese medicine composition for improving fatty liver as well as preparation method, extract, application and preparation thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493307A (en) * | 2001-12-26 | 2004-05-05 | 云南七王制药有限公司 | Fatty liver eliminating pill and its preparation process |
-
2005
- 2005-10-21 CN CNB2005100110801A patent/CN100388945C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1493307A (en) * | 2001-12-26 | 2004-05-05 | 云南七王制药有限公司 | Fatty liver eliminating pill and its preparation process |
Non-Patent Citations (2)
| Title |
|---|
| 祁白术治疗脾虚证小鼠对消化器官组化和超微结构的影响. 许长照等.中国中西医结合消化杂志，第9卷第5期. 2001 |
| 祁白术治疗脾虚证小鼠对消化器官组化和超微结构的影响. 许长照等.中国中西医结合消化杂志，第9卷第5期. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1772257A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN101199618A (en) | Shenling know luo capsule | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN100388945C (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN102283956B (en) | Orally administered drug for treating chronic hepatitis | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101757281B (en) | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof | |
| CN101095768A (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN103230457B (en) | A kind of Chinese medicine composition treating viral myocarditis and preparation method thereof and purposes | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN105769957B (en) | Pseudo-ginseng powder prepared from snow pears and rice water, preparation of pseudo-ginseng powder and preparation method | |
| CN101549045B (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN102430008B (en) | Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN100431595C (en) | Medicinal composition for treating qi stagnation and cold stasis stomach-ache and its preparing method and use | |
| CN115089661A (en) | Application of ginseng composition for assisting in regulating endocrine metabolism and resisting and preventing cancer | |
| CN108888735B (en) | Traditional Chinese medicine composition for treating chronic constipation | |
| CN101658656A (en) | Medicine for curing cholelithiasis | |
| CN102430009A (en) | Traditional Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
| CN103784690B (en) | One treats cardiopathic Chinese medicine composition | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN101032613B (en) | Hepatic cyst-treating Chinese traditional medicine preparation and its preparation process | |
| CN104721595A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia | |
| CN102772630B (en) | Medicine for treating type-II diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: DIHON PHARMACEUTICAL GROUP YUXI BIOPHARMACEUTICAL Free format text: FORMER NAME: YUNNAN YUXI WANGZILONG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 653100 Yunnan city of Yuxi Province in Yuxi high tech Industrial Development Zone Road Patentee after: Yunnan rainbow Pharmaceutical Group Yuxi biological pharmacy Co., Ltd. Address before: 653100 Yunnan city of Yuxi Province in Yuxi high tech Industrial Development Zone Road Patentee before: Yunnan Yuxi Wangzilong Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN YUYAO BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: DIHON PHARMACEUTICAL GROUP YUXI BIOPHARMACEUTICAL CO.,LTD. |
|
| CP03 | Change of name, title or address |
Address after: 653100 hi tech Development Zone, Yunnan, Yuxi Patentee after: Yunnan Yu Yao Biology Pharmacy Co., Ltd Address before: 653100 Yunnan city of Yuxi Province in Yuxi high tech Industrial Development Zone Road Patentee before: Yunnan rainbow Pharmaceutical Group Yuxi biological pharmacy Co., Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Jiu Ying Inventor before: Gao Jiaxiong |
|
| COR | Change of bibliographic data | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fatty liver treating notoginseng prepn and its prepn process Effective date of registration: 20200330 Granted publication date: 20080521 Pledgee: Industrial Bank Co., Ltd. Kunming Branch Pledgor: YUNNAN YUYAO BIOPHARMACEUTICAL Co.,Ltd. Registration number: Y2020530000008 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |